[{"address1": "5505 Morehouse Drive", "address2": "Suite 100", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 267 4467", "website": "https://www.artivabio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/ microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of solid tumors; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. The company was incorporated in 2019 and is headquartered in San Diego, California.", "fullTimeEmployees": 89, "companyOfficers": [{"maxAge": 1, "name": "Dr. Fred  Aslan M.D.", "age": 48, "title": "President, CEO & Director", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 917304, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  Flynn Ph.D.", "age": 50, "title": "Co-Founder & Strategic Advisor", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 499368, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer Kinsbruner Bush Esq., J.D.", "age": 49, "title": "Executive VP, COO, Chief Legal Officer, Corporate Secretary & Compliance Officer", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 630312, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher P. Horan", "age": 56, "title": "Chief Technical Operations Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 612234, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Neha  Krishnamohan", "age": 36, "title": "CFO & Executive VP of Corporate Development", "yearBorn": 1988, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Thorsten  Graef M.D., Ph.D.", "age": 47, "title": "Chief Medical Officer", "yearBorn": 1977, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Heather  Raymon Ph.D.", "age": 60, "title": "Senior Vice President of Research & Early Development", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Moriarty Ph.D.", "title": "Senior VP of Clinical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin  Dewees", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Feng  Xu", "title": "Senior Vice President of Biometrics", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.84, "open": 1.82, "dayLow": 1.8001, "dayHigh": 1.98, "regularMarketPreviousClose": 1.84, "regularMarketOpen": 1.82, "regularMarketDayLow": 1.8001, "regularMarketDayHigh": 1.98, "payoutRatio": 0.0, "forwardPE": -0.57391304, "volume": 180671, "regularMarketVolume": 180671, "averageVolume": 268977, "averageVolume10days": 1145380, "averageDailyVolume10Day": 1145380, "bid": 1.93, "ask": 2.02, "bidSize": 1, "askSize": 1, "marketCap": 48238940, "fiftyTwoWeekLow": 1.78, "fiftyTwoWeekHigh": 17.31, "priceToSalesTrailing12Months": 192.18701, "fiftyDayAverage": 4.0246, "twoHundredDayAverage": 9.269266, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -111627992, "profitMargins": 0.0, "floatShares": 4396812, "sharesOutstanding": 24363100, "sharesShort": 854100, "sharesShortPriorMonth": 1183120, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0352, "heldPercentInsiders": 0.22633, "heldPercentInstitutions": 0.90846, "shortRatio": 9.98, "shortPercentOfFloat": 0.0354, "impliedSharesOutstanding": 24363100, "bookValue": 7.683, "priceToBook": 0.25771183, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -65373000, "trailingEps": -5.81, "forwardEps": -3.45, "enterpriseToRevenue": -444.733, "enterpriseToEbitda": 1.721, "52WeekChange": -0.835, "SandP52WeekChange": 0.059571505, "quoteType": "EQUITY", "currentPrice": 1.98, "targetHighPrice": 23.0, "targetLowPrice": 18.0, "targetMeanPrice": 20.4, "targetMedianPrice": 20.0, "recommendationKey": "none", "numberOfAnalystOpinions": 5, "totalCash": 185428000, "totalCashPerShare": 7.611, "ebitda": -64851000, "totalDebt": 14354000, "quickRatio": 15.219, "currentRatio": 15.395, "totalRevenue": 251000, "debtToEquity": 7.691, "revenuePerShare": 0.022, "returnOnAssets": -0.26725, "returnOnEquity": -0.54243, "grossProfits": 251000, "freeCashflow": -33753248, "operatingCashflow": -55032000, "revenueGrowth": -1.0, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -268.0558, "financialCurrency": "USD", "symbol": "ARTV", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Artiva Biotherapeutics, Inc.", "longName": "Artiva Biotherapeutics, Inc.", "fiftyTwoWeekHighChangePercent": -0.8856153, "fiftyTwoWeekChangePercent": -83.5, "earningsTimestamp": 1742846700, "earningsTimestampStart": 1742846700, "earningsTimestampEnd": 1742846700, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -5.81, "epsForward": -3.45, "epsCurrentYear": -2.54, "priceEpsCurrentYear": -0.7795276, "fiftyDayAverageChange": -2.0446, "fiftyDayAverageChangePercent": -0.50802565, "twoHundredDayAverageChange": -7.289266, "twoHundredDayAverageChangePercent": -0.78639084, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2024-07-19", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1744412020, "regularMarketTime": 1744401601, "exchange": "NGM", "messageBoardId": "finmb_672643147", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 7.6086946, "regularMarketPrice": 1.98, "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1721395800000, "postMarketChangePercent": 0.0, "postMarketPrice": 1.98, "postMarketChange": 0.0, "regularMarketChange": 0.13999999, "regularMarketDayRange": "1.8001 - 1.98", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 268977, "fiftyTwoWeekLowChange": 0.20000005, "fiftyTwoWeekLowChangePercent": 0.112359576, "fiftyTwoWeekRange": "1.78 - 17.31", "fiftyTwoWeekHighChange": -15.33, "displayName": "Artiva Biotherapeutics", "trailingPegRatio": null, "__fetch_time": "2025-04-12"}]